Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2005
10/06/2005US20050222041 oligopeptides capable of stimulating neural cell adhesion molecule (NCAM) signalling and/or interfering with cell adhesion, used for treatment of nervous system disorders
10/06/2005US20050222025 Method of inhibiting fibrosis with a somatostatin agonist
10/06/2005US20050222020 Apoptotically active peptides
10/06/2005US20050222017 Apoptosis promoter and inhibitor interacting with cgi-94, and method of screening the same
10/06/2005US20050222011 Selectin ligands
10/06/2005US20050221477 Protein sustaining undifferentiated stem cells as such
10/06/2005US20050221460 Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton
10/06/2005US20050221434 Receptor of the EDb-fibronectin domains
10/06/2005US20050221381 Method for isolating ligands
10/06/2005US20050221368 Methods for identifying RNA binding compounds
10/06/2005US20050221347 Inhibitors of binding between proteins and macromolecular ligands
10/06/2005US20050221346 May be used to detect the presence of a cancer or to evaluate the prognosis of a known disease
10/06/2005US20050221317 Use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
10/06/2005US20050221287 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation
10/06/2005US20050220958 Pasteurisation process for microbial cells and microbial oil
10/06/2005US20050220857 Physiologically compatible, phospholipid-containing, stable and hard matrix
10/06/2005US20050220855 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease
10/06/2005US20050220823 Ophthalmic composition comprising ascomycin
10/06/2005US20050220806 Method of transporting physiological polymer using protein having rxp repeated sequence
10/06/2005US20050220790 Amino-terminally truncated rantes as chemokine antagonists
10/06/2005US20050220784 Quinazoline derivatives as medicaments
10/06/2005US20050220715 Methods and compositions for improving drug safety
10/06/2005DE20122435U1 Mikronisiertes Zolpidem-Hemitartrat Micronized zolpidem hemitartrate
10/06/2005CA2561502A1 Marker gene for arthrorheumatism test
10/06/2005CA2561495A1 Truncated dance, dance complex and method of using these
10/06/2005CA2534445A1 Agent for promoting hgf production comprising heparin-like oligosaccharides
10/05/2005EP1582586A1 Apoptosis-associated protein and use thereof
10/05/2005EP1582585A1 Method of selecting novel immunosuppressant
10/05/2005EP1582521A1 Fused furan compound
10/05/2005EP1582520A1 Novel parp inhibitors
10/05/2005EP1582517A1 Blood-brain barrier disruption inhibitors
10/05/2005EP1582223A1 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy
10/05/2005EP1582220A1 Composition for topical anesthesia
10/05/2005EP1582216A1 Remedy for pemphigoid
10/05/2005EP1582215A1 Method of inhibiting cell death, cell death inhibitor and remedy for disease caused by cell death containing the cell death inhibitor
10/05/2005EP1582211A1 Jnk inhibitor
10/05/2005EP1582208A2 An amino acid compositions for promoting collagen synthesis
10/05/2005EP1582206A1 Water-soluble composition containing coenzyme q10
10/05/2005EP1582195A1 Whitening agent, skin preparation for external use and cosmetic
10/05/2005EP1581552A2 Human and non-human primate homologues of nkd protein, nucleic acid sequences encoding, and uses thereof
10/05/2005EP1581533A2 Novel benzonaphthyridines
10/05/2005EP1581527A2 Thrombopoietin mimetics
10/05/2005EP1581261A1 Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
10/05/2005EP1581223A2 Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
10/05/2005EP1385536B1 Preparations containing a combination of vitamin e and afamin
10/05/2005EP1294393B1 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment and diagnosis of athersclerosis
10/05/2005EP1272168B1 Small organic molecule regulators of cell proliferation
10/05/2005EP1263430B1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases
10/05/2005EP1233950B1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
10/05/2005EP1230217B1 Positive modulators of nicotinic receptor agonists
10/05/2005EP1202733B1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
10/05/2005EP1183233B1 Bradykinin receptor antagonists
10/05/2005EP1131410B1 Bioengineered tissue constructs and methods for producing and using them
10/05/2005EP1077936B1 Novel analogs of 16-hydroxyeicosatetraenoic acid
10/05/2005EP0990002B1 Dextran derivatives, preparation method and applications as medicine with specific biological action
10/05/2005EP0939632B1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
10/05/2005EP0821590B1 Large area submucosal graft constructs and method for making the same
10/05/2005CN1678734A Differentiation modulating agents and uses therefor
10/05/2005CN1678633A Anti-IGF-I receptor antibody
10/05/2005CN1678628A Stress proteins and peptides and methods of use thereof
10/05/2005CN1678626A Estrieno[3, 2-b]/[3, 4-c]pyrrole derivatives useful as modulators of the estrogen receptors
10/05/2005CN1678621A Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
10/05/2005CN1678612A Viral inhibitors
10/05/2005CN1678611A Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist
10/05/2005CN1678607A Nitrogen-containing aromatic ring derivatives
10/05/2005CN1678606A Novel crystals
10/05/2005CN1678597A Novel quaternary ammonium compounds
10/05/2005CN1678590A Amide derivative and medicine
10/05/2005CN1678585A Therapeutic agents useful for treating pain
10/05/2005CN1678583A Organic acid salt of amlodipine
10/05/2005CN1678579A Indole-3-sulphur derivatives
10/05/2005CN1678576A Pyrrolidine derivatives as oxytocin antagonists
10/05/2005CN1678575A Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
10/05/2005CN1678573A Diarylurea derivatives and their use as chloride channel blockers
10/05/2005CN1678572A Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
10/05/2005CN1678524A Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate
10/05/2005CN1678350A Remedy
10/05/2005CN1678348A Compositions and methods for therapeutic treatment
10/05/2005CN1678347A Antibodies and uses thereof
10/05/2005CN1678338A Method and composition for regulating the activity of regulatory T cells
10/05/2005CN1678334A New plant based agents as bioavailability/bioefficacy enhancers for drugs and nutraceuticals
10/05/2005CN1678332A Novel therapeutic use of polypodium extracts
10/05/2005CN1678330A Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy
10/05/2005CN1678326A 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
10/05/2005CN1678323A Use of polyunsaturated ketones for the treatment of psoriasis
10/05/2005CN1678322A New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2, 3-D]pyrimidine
10/05/2005CN1678315A Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
10/05/2005CN1678314A Glycinamide derivatives as raf-kinase inhibitors
10/05/2005CN1678307A Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors
10/05/2005CN1678304A PKC activation as a means for enhancing aAPP-a secretion and improving cognition using bryostatin type compounds
10/05/2005CN1678299A Composition based on triethyl citrate for the treatment of bacterial infections of the skin
10/05/2005CN1678298A Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
10/05/2005CN1221570C Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
10/05/2005CN1221565C Peptides and their derivatives thereof showing cell attachment, spreading and detachment activity
10/05/2005CN1221551C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/05/2005CN1221549C Crystalline monohydrate, method for producing the same and the use thereof in the production of medicament
10/05/2005CN1221535C Spiroimidazolidine derivatives, their prepn. their use and pharmaceutical preparation comprising them
10/05/2005CN1221529C Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides
10/05/2005CN1221524C Diphenyl ether compounds useful in therapy
10/05/2005CN1221269C Paralysis treating medicine pills
1 ... 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 ... 1564